Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.~* A male or female, aged 18 years or older and having reached the age of legal consent, on the date the informed consent is signed.~* Written informed consent obtained from the subject.~* Subject who has received an ABO compatible allogeneic renal transplant.~* Subject receiving maintenance immunosuppressive therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to the first vaccination.~* Subject without an episode of allograft rejection over the previous three months (90 days) prior to the first vaccination.~* Subject with stable renal function, stability defined as:~  * less than 20% variability between last two creatinine measurements or calculated GFR~ * or in the opinion of the investigator after investigator review of more than the last two creatinine measurements or calculated GFRs.~* Subject not less than 4 months (120 days) and not more than 18 months (547 days) after allograft transplantation at the time of the first vaccination.~* Subjects with multiple dialysis options (peritoneal and/or more than one anatomical access site for haemodialysis) in the event acute or chronic dialysis is needed.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of the first vaccination, and~ * has agreed to continue adequate contraception during the primary treatment period and for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Any primary kidney disease with a high incidence of recurrent primary kidney disease.~* Evidence of recurrent primary kidney disease within the current allograft.~* Previous allograft loss secondary to recurrent primary kidney disease.~  * Multiple kidney transplants are allowed if the reason for a previous allograft's loss is not recurrent primary kidney disease.~* More than one organ transplanted (i.e. kidney-liver, double kidney or kidney-other organ(s) transplanted).~* History of events that, in the opinion of the investigator, may put subject at increased risk for chronic allograft dysfunction (e.g. delayed graft function, peri-operative complications).~* Histologic reports of chronic allograft injury (e.g. transplant glomerulopathy, arteriopathy, C4d deposition).~* Evidence of significant proteinuria in the opinion of the investigator.~* Panel reactive antibody score (PRA or cPRA) that is unknown at the time of transplant.~* Any autoimmune or potential immune-mediated disease including primary kidney disease.~* Use of anti-CD20 or other B-cell monoclonal antibody agents (e.g., rituximab) as induction, maintenance and/or therapeutic immunosuppressive therapy for the prevention of allograft rejection within 9 months (274 days) of first dose of study vaccine/placebo.~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period.~* Concurrent or planned participation in another clinical study, at any time during the study period, which has exposed or will expose the subject to an investigational or a non-registered product~* Administration or planned administration of a live vaccine within 30 days prior to the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.~* Planned administration during the study of a varicella or HZ vaccine other than the study vaccine.~* Previous vaccination against HZ or varicella within the 12 months preceding the first dose of study vaccine/placebo.~* Occurrence of varicella or HZ per clinical history, within the 12 months preceding the first dose of study vaccine/placebo.~* Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit.~* Evidence or high suspicion, in the opinion of the investigator, of noncompliance or nonadherence to use of induction and/or maintenance immunosuppressive therapies.~* Any confirmed or suspected HIV, primary immunodeficiency disease, disseminated or untreated malignancy, or systemic infection.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine or study material and equipment.~* Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe.~* Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.~* Acute disease and/or fever at the time of vaccination.~  * Fever is defined as temperature ≥ 37.5°C /99.5°F by oral route. The preferred route for recording temperature in this study will be oral.~ * Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 3.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1437173A Group (Type: EXPERIMENTAL): Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete